Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetazolamide and Levamisole in Advanced HCC
NCT04611373Phase 3Unknown
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- May 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of acetazolamide and levamisole in hepatocellular carcinoma (HCC), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Progression-Free Survival at 24 months. Status: unknown.
02
Drugs
acetazolamidelevamisole
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04611373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04611373.